Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-09-18 00:00:00 ET · period of report 2024-09-16 · accession 0002001011-24-000082 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-09-18 | 2024-09-16 | LGND | Korenberg Matthew E | Pres, COO | M - OptEx | $58.49 | +5,774 | 51.0K | +13% | +$337.7K |
| DM | 2024-09-18 | 2024-09-16 | LGND | Korenberg Matthew E | Pres, COO | F - Tax | $105.00 | -3,214 | 49.9K | -6% | -$337.5K |
| DM | 2024-09-18 | 2024-09-16 | LGND | Korenberg Matthew E | Pres, COO | M - OptEx | $0.00 | -5,774 | 25.9K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-16 | M | A | 849 | $58.49 | 50,788 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-16 | M | A | 914 | $55.75 | 50,424 | D | — | — | |
| 3 | Common | Common Stock | 2024-09-16 | M | A | 3,340 | $60.94 | 54,008 | D | — | — | |
| 4 | Common | Common Stock | 2024-09-16 | F | D | 319 | $105.00 | 50,668 | D | — | — | |
| 5 | Common | Common Stock | 2024-09-16 | F | D | 1,938 | $105.00 | 52,070 | D | — | — | |
| 6 | Common | Common Stock | 2024-09-16 | M | A | 671 | $49.99 | 50,987 | D | — | — | |
| 7 | Common | Common Stock | 2024-09-16 | F | D | 472 | $105.00 | 50,316 | D | — | — | |
| 8 | Common | Common Stock | 2024-09-16 | F | D | 485 | $105.00 | 49,939 | D | — | — | |
| 9 | Derivative | Employee Stock Option (right to buy) | 2024-09-16 | M | D | 3,340 | $0.00 | 18,500 | D | $60.94 · — to 2025-08-06 | 3,340 Common Stock | (F4) This Option was previously reported as a Grant of 25,000 shares on August 06, 2015, which vested in full on August 06, 2019, at an exercise price of $104.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 10 | Derivative | Employee Stock Option (right to buy) | 2024-09-16 | M | D | 849 | $0.00 | 12,452 | D | $58.49 · — to 2027-02-24 | 849 Common Stock | (F3) This Option was previously reported as a Grant of 15,225 shares on February 24, 2017, which vested in full on February 24, 2021, at an exercise price of $100.38 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 11 | Derivative | Employee Stock Option (right to buy) | 2024-09-16 | M | D | 671 | $0.00 | 5,377 | D | $49.99 · — to 2026-02-11 | 671 Common Stock | (F1) This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 12 | Derivative | Employee Stock Option (right to buy) | 2024-09-16 | M | D | 914 | $0.00 | 25,949 | D | $55.75 · — to 2030-02-13 | 914 Common Stock | (F2) This Option was previously reported as a Grant of 30,750 shares on February 13, 2020, at an exercise price of $95.68 per share , but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on February 13, 2024. |